{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:05:13Z","timestamp":1789877113005,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejmech.2021.113380","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T04:24:28Z","timestamp":1616041468000},"page":"113380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors"],"prefix":"10.1016","volume":"217","author":[{"given":"Lin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianguang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasulu","family":"Cherukupalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113380_bib1","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1128\/AAC.00591-12","article-title":"Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors","volume":"56","author":"Asahchop","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113380_bib2","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV drug discovery and development: current innovations and future trends","volume":"59","author":"Zhan","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113380_bib3","series-title":"Fact Sheet","year":"2019"},{"key":"10.1016\/j.ejmech.2021.113380_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Men\u00e9ndez-Arias","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2021.113380_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF02171653","article-title":"HIV life cycle and genetic approaches","volume":"1","author":"Ratner","year":"1993","journal-title":"Perspect. Drug Discov. Des."},{"key":"10.1016\/j.ejmech.2021.113380_bib6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrmicro3490","article-title":"HIV-1 assembly, release and maturation","volume":"13","author":"Freed","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2021.113380_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coviro.2012.12.002","article-title":"HIV-1 entry inhibitors: recent development and clinical use","volume":"3","author":"Henrich","year":"2013","journal-title":"Current Opinion in Virology"},{"key":"10.1016\/j.ejmech.2021.113380_bib8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nsb0996-763","article-title":"Crystal structure of dimeric HIV-1 capsid protein","volume":"3","author":"Momany","year":"1996","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ejmech.2021.113380_bib9","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cell.2009.04.063","article-title":"X-ray structures of the hexameric building block of the HIV capsid","volume":"137","author":"Pornillos","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.113380_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12250-019-00095-3","article-title":"Multiple roles of HIV-1 capsid during the virus replication cycle","volume":"34","author":"Novikova","year":"2019","journal-title":"Virol. Sin."},{"key":"10.1016\/j.ejmech.2021.113380_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cell.2007.08.018","article-title":"Structure of full-length HIV-1 CA: a model for the mature capsid lattice","volume":"131","author":"Ganser-Pornillos","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.113380_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12977-016-0262-0","article-title":"HIV-1 capsid is involved in post-nuclear entry steps","volume":"13","author":"Chen","year":"2016","journal-title":"Retrovirology"},{"key":"10.1016\/j.ejmech.2021.113380_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8420","article-title":"Reconstitution and visualization of HIV-1 capsid-dependent replication and integration in\u00a0vitro","volume":"370","author":"Christensen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113380_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.virusres.2014.07.010","article-title":"Roles of HIV-1 capsid in viral replication and immune evasion","volume":"193","author":"Le Sage","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.ejmech.2021.113380_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/1570162X14999160224103555","article-title":"HIV-1 capsid inhibitors as antiretroviral agents","volume":"14","author":"Thenin-Houssier","year":"2016","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.ejmech.2021.113380_bib16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0022-2836(03)00289-4","article-title":"Antiviral inhibition of the HIV-1 capsid protein","volume":"327","author":"Tang","year":"2003","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113380_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jmb.2007.07.070","article-title":"Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein","volume":"373","author":"Kelly","year":"2007","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113380_bib18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jmb.2010.11.027","article-title":"Structure of the HIV-1 full-length capsid protein in a conformationally trapped unassembled state induced by small-molecule binding","volume":"406","author":"Du","year":"2011","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113380_bib19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bmcl.2010.10.131","article-title":"Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly","volume":"21","author":"Fader","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113380_bib20","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1016\/j.bmcl.2013.03.073","article-title":"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: addressing configurational instability through scaffold modification","volume":"23","author":"Fader","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113380_bib21","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1016\/j.bmcl.2013.03.074","article-title":"Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moiety","volume":"23","author":"Fader","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113380_bib22","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1016\/j.bmcl.2012.10.034","article-title":"Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold","volume":"22","author":"Tremblay","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113380_bib23","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1128\/JVI.00493-12","article-title":"Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein","volume":"86","author":"Lemke","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.113380_bib24","doi-asserted-by":"crossref","first-page":"8472","DOI":"10.1128\/JVI.05006-11","article-title":"Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid","volume":"86","author":"Kortagere","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.113380_bib25","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1107\/S0907444913006409","article-title":"A\u00a0novel inhibitor-binding site on the HIV-1 capsid N-terminal domain leads to improved crystallization via compound-mediated dimerization","volume":"69","author":"Lemke","year":"2013","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2021.113380_bib26","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1128\/AAC.00985-13","article-title":"Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes","volume":"57","author":"Lamorte","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113380_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004459","article-title":"Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly","volume":"10","author":"Price","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2021.113380_bib28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nsmb964","article-title":"A\u00a0peptide inhibitor of HIV-1 assembly in\u00a0vitro","volume":"12","author":"Sticht","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113380_bib29","doi-asserted-by":"crossref","first-page":"32024","DOI":"10.1074\/jbc.M804230200","article-title":"Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein","volume":"283","author":"Bartonova","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113380_bib30","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jmb.2008.02.066","article-title":"A\u00a0cell-penetrating helical peptide as a potential HIV-1 inhibitor","volume":"378","author":"Zhang","year":"2008","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113380_bib31","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1128\/AAC.02574-15","article-title":"Ebselen, a small-molecule capsid inhibitor of HIV-1 replication","volume":"60","author":"Thenin-Houssier","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113380_bib32","first-page":"545","article-title":"Specific inhibitors of HIV capsid assembly binding to the C-terminal domain of the capsid protein: evaluation of 2-arylquinazolines as potential antiviral compounds","volume":"59","author":"Machara","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113380_bib33","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1016\/j.bmcl.2016.06.039","article-title":"Synthesis and evaluation of 2-pyridinylpyrimidines as inhibitors of HIV-1 structural protein assembly","volume":"26","author":"Ko\u017e\u00ed\u0161ek","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113380_bib34","doi-asserted-by":"crossref","first-page":"115488","DOI":"10.1016\/j.bmc.2020.115488","article-title":"Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment","volume":"28","author":"Tsuji","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113380_bib35","doi-asserted-by":"crossref","first-page":"115923","DOI":"10.1016\/j.bmc.2020.115923","article-title":"Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment","volume":"30","author":"Tsuji","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113380_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001220","article-title":"HIV capsid is a tractable target for small molecule therapeutic intervention","volume":"6","author":"Blair","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2021.113380_bib37","doi-asserted-by":"crossref","first-page":"18625","DOI":"10.1073\/pnas.1419945112","article-title":"Structural basis of HIV-1 capsid recognition by PF74 and CPSF6","volume":"111","author":"Bhattacharya","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2021.113380_bib38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1128\/JVI.01406-10","article-title":"Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization","volume":"85","author":"Shi","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.113380_bib39","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1128\/JVI.03116-15","article-title":"Roles of capsid-interacting host factors in multimodal inhibition of HIV-1 by PF74","volume":"90","author":"Saito","year":"2016","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.113380_bib40","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41591-019-0560-x","article-title":"A\u00a0highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model","volume":"25","author":"Yant","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2021.113380_bib41","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.113380_bib42","series-title":"Preparation of Cyclopropacyclopentapyrazolylacetamide Compounds Useful for Treatment of Multidrug Resistant HIV Infections","first-page":"226pp","author":"Bauer","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113380_bib43","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1126\/science.abb4808","article-title":"Structural and mechanistic bases for a potent HIV-1 capsid inhibitor","volume":"370","author":"Bester","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113380_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02057-20","article-title":"Absence of lenacapavir (GS-6207) phenotypic resistance in HIV gag cleavage site mutants and in isolates with resistance to existing drug classes","volume":"65","author":"Margot","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2021.113380_bib45","series-title":"Preparation of 4-Oxo-3,4-Dihydroquinazoline Compds. As Inhibitors of Human Immunodeficiency Virus Replication","first-page":"313pp","author":"Belema","year":"2019"},{"key":"10.1016\/j.ejmech.2021.113380_bib46","series-title":"Indazolylquinazolinones as Inhibitors of Human Immunodeficiency Virus Replication and Their Preparation","first-page":"277pp","author":"Gillis","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113380_bib47","series-title":"Indazolylquinazolinones as Inhibitors of Human Immunodeficiency Virus Replication and Their Preparation","first-page":"118pp","author":"Gillis","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113380_bib48","series-title":"Indazolylquinazolinones as Inhibitors of Human Immunodeficiency Virus Replication and Their Preparation","first-page":"171pp","author":"Bowsher","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113380_bib49","series-title":"Indazolylquinazolinone Derivatives as Inhibitors of Human Immunodeficiency Virus Replication and Their Preparation","first-page":"150pp","author":"Bowsher","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113380_bib50","series-title":"Preparation of Quinazolinyl-Indazole Derivatives and Their Use as Inhibitors of Human Immunodeficiency Virus Replication","first-page":"98pp","author":"Bowsher","year":"2020"},{"key":"10.1016\/j.ejmech.2021.113380_bib51","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ejmech.2018.09.029","article-title":"Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library","volume":"158","author":"Wu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113380_bib52","doi-asserted-by":"crossref","first-page":"28961","DOI":"10.1039\/C9RA05869A","article-title":"Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors","volume":"9","author":"Jiang","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2021.113380_bib53","doi-asserted-by":"crossref","first-page":"112085","DOI":"10.1016\/j.ejmech.2020.112085","article-title":"Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities","volume":"190","author":"Sun","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113380_bib54","first-page":"4790","article-title":"Design, synthesis, and mechanism study of benzenesulfonamide-containing phenylalanine derivatives as novel HIV-1 capsid inhibitors with improved antiviral activities","volume":"63","author":"Sun","year":"2020","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113380_bib55","doi-asserted-by":"crossref","first-page":"106220","DOI":"10.1016\/j.ijantimicag.2020.106220","article-title":"Long-acting drugs and formulations for the treatment and prevention of HIV infection","volume":"57","author":"Flexner","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2021.113380_bib56","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.4155\/fmc-2020-0084","article-title":"Medicinal chemistry strategies of targeting HIV-1 capsid protein for antiviral treatment","volume":"12","author":"Xu","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113380_bib57","first-page":"9375","article-title":"Overview of recent strategic advances in medicinal chemistry","volume":"62","author":"Wu","year":"2019","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421002294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421002294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:27:06Z","timestamp":1759328826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421002294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":57,"alternative-id":["S0223523421002294"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113380","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113380"}}